A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Vicinity Motor Corp (CVE:VMC) (OTCQX:BUSXF) (FRA:6LG) reported a 588% year-over-year increase in its first quarter 2021 revenue to C$27.3 million as the company delivered 67 buses during the period, about 10 times more than a year ago. Vicinity also swung to a quarterly profit $2.0 million, or $0.07 per share, from a net loss of $1.7 million, or $0.07 per share, in the same quarter a year earlier.
Midwest Energy Emissions Corp (OTCQB:MEEC) (ME2C Environmental) reported its 1Q results showing a 171% bump in year-over-year revenue at $3 million for the quarter. The environmental technologies firm saw most of its revenue come from sorbent product sales, which hit $2 million. During the three-month period to end March 31, 2021, ME2C strengthened its balance sheet by eliminating $1.85 million in convertible debt.
Pharmadrug Inc.: PharmaDrug Signs Supply Agreement with European Cannabis Extractor for Medical Grade THC Oil to Be Sold Under PharmaDrug Brand
PharmaDrug or the
Company ) a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a supply agreement (the
Supply Agreement ) with an emerging Eurozone cannabis extractor for medical grade THC oil to be sold under PharmaDrug s own brand. The Company expects to receive product and begin selling in Germany by September of 2021.
Pursuant to the Supply Agreement, the Company s licensed German distributor, Pharmadrug Production GmbH (
PharmaDrug promotes Dr Paul Van Slyke to Chief Scientific Officer for whole group
Van Slyke previously served as the CSO on a consultancy basis of biotech and subsidiary Sairiyo Therapeutics, which PharmaDrug recently acquired Given the advancements in Cepharanthine activities and the quickly evolving DMT strategy, PharmaDrug said it felt Van Slyke s attention was needed on an exclusive and full-time basis
PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) has named entrepreneur-scientist and experienced pharma executive Dr Paul Van Slyke as the new Chief Scientific Officer (CSO) for the group.
Van Slyke previously served as the CSO on a consultancy basis of biotech and subsidiary Sairiyo Therapeutics, which PharmaDrug recently acquired.